FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation awarded to MimiVax Inc. now applies to …